Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed With Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs . J of Skin 2024, 8 (1), s336. https://doi.org/10.25251/skin.8.supp.336.